Patent · US Active

PCSK9 targeting oligonucleotides for treating hypercholesterolemia and related conditions

US11566248B2 · kind B2 · utility

1Cited by
0References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 1, 2019
Grant dateJan 31, 2023
Priority date—
Expiry dateApr 1, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Y304/21061
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

This disclosure relates to oligonucleotides, compositions and methods useful for reducing PCSK9 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of PCSK9 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of PCSK9 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat hypercholesterolemia, atherosclerosis, and/or one or more symptoms or complications thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.